Obtaining Exposures of Metabolites in Preclinical Species through Plasma Pooling and Quantitative NMR: Addressing Metabolites in Safety Testing (MIST) Guidance without Using Radiolabeled Compounds and Chemically Synthesized Metabolite Standards-Reference-Cited by-同舟云学术

Obtaining Exposures of Metabolites in Preclinical Species through Plasma Pooling and Quantitative NMR: Addressing Metabolites in Safety Testing (MIST) Guidance without Using Radiolabeled Compounds and Chemically Synthesized Metabolite Standards

Published:2008-12-10 Issue:2 Volume:22 Page:311-322
ISSN:0893-228X
Container-title:Chemical Research in Toxicology
language:en
Short-container-title:Chem. Res. Toxicol.

Author:

Vishwanathan Karthick¹,Babalola Kathlene¹,Wang Jack¹,Espina Robert¹,Yu Linning¹,Adedoyin Adedayo¹,Talaat Rasmy¹,Mutlib Abdul¹,Scatina JoAnn¹

Affiliation:

1. Biotransformation, Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426

Publisher

American Chemical Society (ACS)

Subject

Toxicology,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/tx8003328

Reference28 articles.

1. A rapid method for quantitatively estimating metabolites in human plasma in the absence of synthetic standards using a combination of liquid chromatography/mass spectrometry and radiometric detection

2. Nuclear Magnetic Resonance Spectroscopy as a Quantitative Tool To Determine the Concentrations of Biologically Produced Metabolites: Implications in Metabolites in Safety Testing

3. Determination of mean valproic acid serum level by assay of a single pooled sample

4. Pooling plasmas for a rapid answer in pharmacokinetic studies: application to a bioequivalence study of hydrocortisone tablets

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group;Clinical Pharmacology & Therapeutics;2023-12-10

2. Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development;Overcoming Obstacles in Drug Discovery and Development;2023

3. Investigating the link between drug metabolism and toxicity;Overcoming Obstacles in Drug Discovery and Development;2023

4. Disproportionate drug metabolites: challenges and solutions;Overcoming Obstacles in Drug Discovery and Development;2023

5. Identification of HDACs Inhibitor E14 Metabolites Appeared in Rat Plasma, Feces and Urine by UPLC-QTOF-MS/MS;Current Pharmaceutical Analysis;2021-07-28